Predominant myosin superrelaxed state in canine myocardium with naturally occurring dilated cardiomyopathy
Related Experiment Video
Updated: Jul 21, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Julien Ochala1, Christopher T A Lewis1, Thomas Beck1
1Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Insights
In dilated cardiomyopathy (DCM), relaxed myosin molecules in dog hearts adopt a superrelaxed state, potentially impairing contractility. This myosin alteration is reversible with the drug EMD-57033, suggesting a new treatment approach for heart failure.
Area of Science:
- Cardiovascular Biology
- Muscle Physiology
- Heart Failure Research
Background:
- Dilated cardiomyopathy (DCM) is a heart failure characterized by reduced contractility.
- The precise cellular and molecular mechanisms underlying DCM remain incompletely understood.
- Myosin's conformational states are critical for cardiac muscle function.
Purpose of the Study:
- To investigate alterations in myosin's relaxed conformational states in canine DCM.
- To assess the impact of DCM on myosin's energetic and structural properties.
- To explore potential therapeutic interventions targeting myosin in DCM.
Main Methods:
- Cardiac muscle strips from DCM Doberman Pinschers and controls were dissected and skinned.
- Mant-ATP chase experiments were used to assess myosin's energetic states.
- X-ray diffraction was employed to analyze myosin's structural conformation.
Main Results:
- DCM hearts showed a significant increase in myosin's superrelaxed (SRX) state compared to controls.
- X-ray diffraction revealed a higher proportion of myosin heads near actin in DCM hearts.
- An uncoupling between energetic (Mant-ATP chase) and structural (X-ray diffraction) data was observed in DCM.
Conclusions:
- Myosin molecules in DCM hearts may be trapped in a nonsequestered, ATP-conserving SRX state.
- This myosin alteration potentially impairs sarcomeric contractility in DCM.
- The drug EMD-57033 demonstrated potential to rescue the DCM-associated myosin alterations, indicating a myosin-centered therapeutic strategy.
Abstract:
Dilated cardiomyopathy (DCM) is a naturally occurring heart failure condition in humans and dogs, notably characterized by a reduced contractility and ejection fraction. As the identification of its underlying cellular and molecular mechanisms remain incomplete, the aim of the present study was to assess whether the molecular motor myosin and its known relaxed conformational states are altered in DCM. For that, we dissected and skinned thin cardiac strips from left ventricle obtained from six DCM Doberman Pinschers and six nonfailing (NF) controls. We then used a combination of Mant-ATP chase experiments and X-ray diffraction to assess both energetic and structural changes of myosin. Using the Mant-ATP chase protocol, we observed that in DCM dogs, the amount of myosin molecules in the ATP-conserving conformational state, also known as superrelaxed (SRX), is significantly increased when compared with NF dogs. This alteration can be rescued by applying EMD-57033, a small molecule activating myosin. Conversely, with X-ray diffraction, we found that in DCM dogs, there is a higher proportion of myosin heads in the vicinity of actin when compared with NF dogs (1,0 to 1,1 intensity ratio). Hence, we observed an uncoupling between energetic (Mant-ATP chase) and structural (X-ray diffraction) data. Taken together, these results may indicate that in the heart of Doberman Pinschers with DCM, myosin molecules are potentially stuck in a nonsequestered but ATP-conserving SRX state, that can be counterbalanced by EMD-57033 demonstrating the potential for a myosin-centered pharmacological treatment of DCM.NEW & NOTEWORTHY The key finding of the present study is that, in left ventricles of dogs with a naturally occurring dilated cardiomyopathy, relaxed myosin molecules favor a nonsequestered superrelaxed state potentially impairing sarcomeric contractility. This alteration is rescuable by applying a small molecule activating myosin known as EMD-57033.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Myocarditis I: Introduction

